Month: June 2019

Viewpoint CSO leads the DOE Lead-212 Users Meeting at SNMMI

June 22, 2019 | Anaheim, CA.

Viewpoint Co-Founder and Chief Science Officer Michael K. Schultz, PhD led the Department of Energy Lead-212 User Meeting at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held in Anaheim, CA. This event is a forum for the radiopharmaceutical community to come together and share respective success and challenges of introducing alpha-particle radionuclide therapy for cancer using lead-212. Dr. Schultz has consecutively led this event at the SNMMI annual meeting for the past three years.

Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting

The initiative introduces the new brand identity for Isoray’s innovative product offerings and focuses on raising awareness of the important advances in the treatment of cancers utilizing brachytherapy powered by Cesium-131, now known as Cesium Blu™.

Viewpoint Awarded $300K NIH Phase I SBIR

June 1, 2019 | Coralville, IA.

Viewpoint Molecular Targeting, Inc. was awarded a $300,000 Small Business Innovation Research (SBIR) Phase I grant by the National Institutes of Health (NIH). This marks a total of over $3M in funding and a total of 7 awards by the NIH to Viewpoint. Each award proves a vetting of Viewpoint’s approach and technology by recognized experts that serve on NIH review committees. These awards aid Viewpoint in the development and acceleration of image-guided therapy and diagnostic products for cancers, such as metastatic melanoma and neuroendocrine tumors.

NIH SBIR programs fund early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small businesses participate in federal research and development to develop life-saving technologies and create jobs.

For more information: About the NIH SBIR Program.

Scroll to top